Progastrine Et Cancers S.a R.l.

Universitè De Montpellier

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Ecs-Progastrin Sa

Centre National De La Recherche Scientifique-Cnrs

Inserm

Université Montpellier Ii

Université De Montpellier 1

Alexandre Prieur

Jean-Marc Lemaitre

Ollivier Milhavet

Laure Lapasset

The present invention relates to combinations comprising anti-progastrin (anti-hPG) monoclonal antibodies and immune checkpoint inhibitors, as well as pharmaceutical compositions comprising said combinations. Methods of treatment of cancer using said combinations are also provided.

Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer

The present invention relates to methods for the in vitro diagnosis of lung cancer in a subject, comprising the detection of progastrin using at least one progastrin-binding antibody. According to the method of the invention, the subject is diagnosed with a lung cancer when progastrin is detected in the sample.

Compositions and methods for detecting lung cancer

The present invention relates to methods for the in vitro diagnosis of esophageal cancer, and to compositions and methods for the prevention or the treatment of esophageal cancer. Disclosed are said compositions that include an antibody binding to progastrin and disclosed are methods that include the use of an antibody binding to progastrin.

Compositions and methods for detecting and treating esophageal cancer

The present invention relates to methods for the in vitro diagnosis of ovarian cancer, and to compositions and methods for the prevention or the treatment of ovarian cancer. Disclosed are compositions that include an antibody binding to progastrin and disclosed are methods that include the use of an antibody binding to progastrin.

Compositions and methods for detecting and treating ovarian cancer

The present invention relates to compositions and methods for the prevention or the treatment of prostate cancer, wherein said compositions comprise an antibody binding to progastrin and said methods comprise the use of an antibody binding to progastrin.

Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule

The present invention relates to compositions and methods for the in vitro diagnosis of prostate cancer, wherein said compositions comprise an antibody binding to progastrin and said methods comprise the use of an antibody binding to progastrin.

Compositions and methods for detecting prostate cancer

The present invention relates to compositions and methods for the prevention or the treatment of lung cancer, wherein the compositions comprise an antibody binding to progastrin and the methods comprise the use of an antibody binding to progastrin.

Compositions and methods for treating lung cancer

The invention relates to a method for reprogramming cells from aged donors or senescent cells to pluripotent cells that have lost marks of senescence. In particular, the invention relates to an ex vivo method for preparing induced pluripotent stem cells (iPSCs) from a target cell population comprising cells from aged donors or senescent cells, said method comprising the steps of culturing said target cell population under appropriate conditions for reprogramming said cells into iPSCs, wherein said appropriate conditions comprises increasing expression in said target cells, of at least the following reprogramming factors: Oct4, Klf4, Sox2, c-Myc, Lin28 and, optionally Nanog.

Growing community of inventors

Montpellier, France

Alexandre Prieur